



## CEO of NLS-1 Pharma AG is honored with Several Illustrious Awards This Summer

**Switzerland, September 1st, 2018** - NLS-1 Pharma AG (NLS), a cutting-edge Swiss biotech firm focusing on the development of novel treatments for Attention-Deficit/Hyperactivity Disorder (ADHD), announces that its CEO and co-founder Alex Zwyer was recently honored with several prestigious awards for pioneering work in ADHD treatment:

- **'One of the 10 Best Performing Leaders to Watch'** (*Insight Success Business Magazine* / USA, July 13, 2018)
- **'Healthcare CEO of the Year - Switzerland'** (*Business Worldwide Magazine* / UK, Aug. 2, 2018)
- **'Most Innovative CEO of the Year - Switzerland'** (*Business Worldwide Magazine* / UK, Aug. 2, 2018)
- **'Most Influential CEO of the Year - Switzerland'** (*CV Magazine* / UK, Aug. 30, 2018)

“I am extremely humbled and grateful for these recognitions, which I dedicate to my entire team” said Mr Zwyer, CEO of NLS. When asked the secret of the company’s success to date, Mr Zwyer puts it down to two important overarching factors; an outstanding team and a patient centred approach. “We are fortunate enough to have an all-star team of research, drug development and commercial leaders in our organisation, with patients at the heart of everything we do. We strive to find better and safer treatment options and will not rest until we have an effective, safe way of managing ADHD” he said.

### **About NLS-1 Pharma AG**

NLS-1 Pharma AG (NLS) is a privately owned, Swiss-based cutting edge biotech firm focusing on the development of first-in-class treatments for ADHD. NLS has built a portfolio of promising clinical-stage medicines being developed by an experienced team of proven experts in ADHD and working closely with key opinion leaders globally.

#### Investor relations & media contact

NLS-1 Pharma AG

Alex Zwyer, CEO : +41 41 618 80 00

[www.nlspharma.com](http://www.nlspharma.com)